Donanemab,Aducanumab
Eli Lilly,Biogen,Eisai
['aducanumab']
more patients with early symptomatic #ad reached amyloid clearance and plaque reductions at 6 months with #donanemab vs. #aducanumab, according to a presentation at #aanam. 
The content you need, when you need it.